Breaking Medical
Technology Stock News: Aethlon Medical (NASDAQ: $AEMD) Enters Into Materials Transfer Agreement for
Santersus AG’s NucleoCapture and HemoNucleoCapture Devices
Aethlon Medical Will Perform Pre-Clinical Studies to Explore Potential
Synergies With its First-in-Class Hemopurifier® Blood Filtration System
SAN DIEGO, CA, February 21, 2024 -- (Investorideas.com
Newswire) Aethlon Medical, Inc. (NASDAQ:AEMD), a medical
therapeutic company focused on developing products to treat cancer and
life-threatening infectious diseases, today announced that it entered into a
Materials Transfer Agreement (MTA) with Santersus AG, a Zurich-London based, privately
held therapeutic medical device company, for Santersus’ NucleoCapture and
HemoNucleoCapture devices.
Read this in full at: https://www.investorideas.com/news/2024/02211AEMD-NucleoCapture-HemoNucleoCapture-Devices.asp
Under the terms
of the MTA, Santersus will supply Aethlon with NucleoCapture and HemoNucleoCapture
devices, designed to remove Neutrophil Extracellular Traps (NETs), which are
toxic to tissues and organs and are implicated in the pathophysiology of cancer,
sepsis, autoimmune diseases, such as lupus, and ischemia reperfusion injury in
organ transplantation.
Aethlon will perform
initial pre-clinical studies to examine the NucleoCapture and HemoNucleoCapture
devices, alone, and in combination with Aethlon’s Hemopurifier® -- a
therapeutic blood filtration system designed to bind and remove harmful
exosomes and life-threatening viruses from blood and other biological fluids --
to assess their ability to remove important targets in samples from cancer
patients, as well as from perfusates from kidneys that have undergone machine
perfusion as part of the renal transplantation process.
"We look
forward to initiating pre-clinical studies shortly, to expand upon the data that
Santersus has generated in sepsis and liver and lung transplantation, and more
importantly, to explore potential synergies with our Hemopurifier, initially in
oncology and renal transplantation, as well as other potential indications,”
stated James Frakes, Interim Chief Executive Officer and Chief Financial
Officer of Aethlon Medical. “Our belief is that the NETs removed by the
NucleoCapture and HemoNucleoCapture devices, in combination with the clinical mediators
removed by our Hemopurifier, could have an additive or synergistic effect in
both the cancer and kidney transplant settings. The signing of the MTA
represents an important milestone for both companies, as it is the first step toward
a potential future collaboration.”
“Our
collaboration with Aethlon has provided us with research and development
partners with expertise and capabilities to help advance our NucleoCapture technology platform forward
in important fields, such as oncology and kidney transplantation. We are excited to continue
building on the progress we've made in Santersus thus far and on taking the
next steps forward in executing on our plans to advance NucleoCapture
technology,” commented Scott Maguire, Chairman of Santersus. “NETs are being increasingly
recognized as an important element in cancer progression and metastasis. We
believe extracorporeal removal of NETs using NucleoCapture either alone or in combination with
Hemopurifier technology might create a transformational treatment option for
patients receiving immune checkpoint inhibitors
or CAR T cell therapies.”
About Santersus AG
Santersus AG is a clinical stage privately held
therapeutic apheresis Anglo-Swiss company. In clinical trials, Santersus’
flagship medical device, NucleoCapture, has demonstrated the removal from patient
blood of Neutrophil Extracellular Traps (NETs). NETs are fibers of decondensed
DNA decorated with cytotoxic proteins that have been released from activated
neutrophils. NETs have been recognized as one of the major driving factors in
the development of sepsis, cancer, acute organ failure, autoimmune flares, and
neurodegeneration, including Alzheimer’s disease. NucleoCapture has been
granted designation as a Breakthrough Device by the US Food & Drug
Administration (FDA). NucleoCapture
blood purification technology is based on biocompatible, highly porous polymer
beads conjugated with proprietary human recombinant histone H1.3 protein.
Histone H1.3 protein was created in nature to act as the ultimate human DNA
binding and compacting protein with single digit nanomolar DNA binding
constants. As a result, in clinical trials Santersus has demonstrated that a
single pass of NETs contaminated blood through the NucleoCapture device results
in over 95% removal of NETs. Santersus has developed NucleoCapture
for the treatment of sepsis, primary graft dysfunction after lung
transplantation, reconditioning of extended criteria donor organs for liver and
lung transplantation and Alzheimer’s disease.
Additional information can be found at www.Santersus.com
About Aethlon and the Hemopurifier®
Aethlon Medical
is a medical therapeutic company focused on developing the Hemopurifier, a
clinical stage immunotherapeutic device which is designed to combat cancer and
life-threatening viral infections and for use in organ transplantation. In
human studies, the Hemopurifier has demonstrated the removal of
life-threatening viruses and in pre-clinical studies, the Hemopurifier has
demonstrated the removal of harmful exosomes from biological fluids, utilizing
its proprietary lectin-based technology. This action has potential applications
in cancer, where exosomes may promote immune suppression and metastasis, and in
life-threatening infectious diseases. The Hemopurifier is a U.S. Food and Drug
Administration (FDA) designated Breakthrough Device indicated for the treatment
of individuals with advanced or metastatic cancer who are either unresponsive
to or intolerant of standard of care therapy, and with cancer types in which
exosomes have been shown to participate in the development or severity of the
disease. The Hemopurifier also holds an FDA Breakthrough Device designation and
an open Investigational Device Exemption (IDE) application related to the
treatment of life-threatening viruses that are not addressed with approved
therapies.
Additional
information can be found at www.AethlonMedical.com.
Forward Looking Statements
This press release contains forward-looking
statements within the meaning of Section 27A of the Securities Act of 1933 and
Section 21E of the Securities Exchange Act of 1934 that involve risks and
uncertainties. Statements containing words such as "may,"
"believe," "anticipate," "expect,"
"intend," "plan," "project," "will,"
"projections," "estimate," "potentially" or
similar expressions constitute forward-looking statements. Such forward-looking
statements are subject to significant risks and uncertainties and actual
results may differ materially from the results anticipated in the
forward-looking statements. These forward-looking statements are based upon
Aethlon's current expectations and involve assumptions that may never
materialize or may prove to be incorrect. Factors that may contribute to such
differences include, without limitation, the Company's ability to successfully raise
additional capital and to complete development of the Hemopurifier and to
successfully demonstrate the utility of the Hemopurifier in cancer and
infectious diseases; the Company’s ability to demonstrate synergies of the
Hemopurifier with the NucleoCapture and HemoNucleoCapture devices;
the Company’s ability to enter into a future collaboration with Santersus; the
Company’s ability to complete the internal binding study of relevant
extracellular vesicles; the Company’s ability to commence and manage its clinical trials; and
other potential risks. The foregoing list of risks and uncertainties is
illustrative, but is not exhaustive. Additional factors that could cause
results to differ materially from those anticipated in forward-looking
statements can be found under the caption "Risk Factors" in the
Company's Annual Report on Form 10-K for the year ended March 31, 2023, and in
the Company's other filings with the Securities and Exchange Commission,
including its quarterly Reports on Form 10-Q. All forward-looking statements
contained in this press release speak only as of the date on which they were
made. Except as may be required by law, the Company does not intend, nor does
it undertake any duty, to update this information to reflect future events or
circumstances.
Company Contact:
Jim Frakes
Interim Chief Executive Officer and Chief Financial Officer
Aethlon Medical, Inc.
Investor Contact:
Susan Noonan
S.A. Noonan Communications, LLC
susan@sanoonan.com
917-513-5303
Aethlon Medical Inc. (Nasdaq:AEMD) is a featured
biotech stock on Investorideas.com
More info on AEMD at
Investorideas.com Visit: https://www.investorideas.com/CO/AEMD/
Get News Alerts on Aethlon Medical
Disclaimer/Disclosure: Investorideas.com is a digital publisher of third party sourced
news, articles and equity research as well as creates original content,
including video, interviews and articles. Original content created by
investorideas is protected by copyright laws other than syndication rights. Our
site does not make recommendations for purchases or sale of stocks, services or
products. Nothing on our sites should be construed as an offer or solicitation
to buy or sell products or securities. All investing involves risk and possible
losses. This site is currently compensated for news publication and
distribution, social media and marketing, content creation and more. Disclosure
is posted for each compensated news release, content published /created if
required but otherwise the news was not compensated for and was published for
the sole interest of our readers and followers. Contact management and IR of
each company directly regarding specific questions. Disclosure: Aethlon
Medical, Inc. (NASDAQ:AEMD) is a paid featured stock on Investorideas.com More
disclaimer info: https://www.investorideas.com/About/News/Clientspecifics.asp
https://www.investorideas.com/About/Disclaimer.asp
Learn more about
publishing your news release and our other news services on the
Investorideas.com newswire https://www.investorideas.com/News-Upload/ Global investors must adhere to regulations of
each country. Please read Investorideas.com privacy policy: https://www.investorideas.com/About/Private_Policy.asp
Biotech
Industry Stocks- investing ideas in biotechnology stocks, medical technology
and life sciences
Like Biotech
Stocks? View our Biotech
Stocks Directory
Get News Alerts on Biotech Stocks
